Breaking News Instant updates and real-time market news.

SNAP

Snap

$13.66

0.115 (0.85%)

, BMY

Bristol-Myers

$56.45

-0.1 (-0.18%)

07:35
07/10/18
07/10
07:35
07/10/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Snap Inc. (SNAP), Bristol Myers Squibb (BMY), Southwest (LUV), PepsiCo (PEP), Endo (ENDP), Stitch Fix (SFIX), Zynga (ZNGA), Scientific Games (SGMS), Pretium Resources (PVG), and Platform Specialty Products (PAH).

SNAP

Snap

$13.66

0.115 (0.85%)

BMY

Bristol-Myers

$56.45

-0.1 (-0.18%)

LUV

Southwest

$53.25

0.52 (0.99%)

PEP

PepsiCo

$107.78

-1.78 (-1.62%)

ENDP

Endo

$11.22

0.365 (3.36%)

SFIX

Stitch Fix

$31.11

-1.3 (-4.01%)

ZNGA

Zynga

$4.24

0.025 (0.59%)

SGMS

Scientific Games

$50.05

1.4 (2.88%)

PVG

Pretium Resources

$9.30

1.205 (14.89%)

PAH

Platform Specialty Products

$12.40

0.66 (5.62%)

  • 10

    Jul

  • 10

    Jul

  • 17

    Jul

  • 26

    Jul

SNAP Snap
$13.66

0.115 (0.85%)

07/05/18
BTIG
07/05/18
NO CHANGE
Target $275
BTIG
Buy
Facebook price target raised to $275 from $175 at BTIG
BTIG analyst Richard Greenfield raised his price target on Facebook (FB) to $275 and kept his Buy rating, saying the company's Instagram business is helping to grow its Mobile Time Spent operating metric. The analyst notes that Instagram now has over 1B users pay day with over 400M stories, calling that growth to the size twice as large as Snapchat (SNAP) "stunning". The analyst also states that consumers "simply could not care less" about the company's privacy practices over the past several years in spite of the regulatory scrutiny in that area across multiple countries. Greenfield contends that Facebook's personal content shift "has notably improved the quality" of the core experience on its platform, positioning the company as a "must-have utility to all demographics."
06/19/18
COWN
06/19/18
NO CHANGE
Target $9
COWN
Underperform
Snap survey shows usage declining, says Cowen
Cowen analyst John Blackledge said his survey of Snap users shows usage is declining on both a monthly and year-over-year time period. The analyst trimmed his estimates and lowered his revenue/EBITDA forecasts following the survey. Blackledge reiterated his Underperform rating and lowered his price target to $9 from $10 on Snap shares.
06/20/18
NEED
06/20/18
NO CHANGE
NEED
Underperform
Snap Q2 revenue forecast reduced at Needham on lower DAU view
Needham analyst Laura Martin lowered her Q2 revenue forecasts on Snap by 15%, saying her channel checks suggest that the Daily Active User count will fall by 3M subscriptions in Q2 to 188M, which is also 6% below her prior estimate. The analyst keeps her Underperform rating, adding that the checks also anticipate a "dramatic slowdown in spending" by brands as a result of the major advertising events like the Grammys, Super Bowl, and NCAA finals not being repeated in Q1. Although Martin raises her Snap EPS forecast to ($1.15) from ($1.22), she attributes that to aggressive cost cutting, noting that her negative view on the company will persist until she sees some positive Daily Active User momentum.
06/06/18
DBAB
06/06/18
NO CHANGE
DBAB
Hold
Audience reach data show improving trends at Snap, says Deutsche Bank
Audience reach data show improving trends at Snap (SNAP) and stability at Facebook (FB) despite the General Data Protection Regulation rollout in Europe, Deutsche Bank analysts Lloyd Walmsley and Kunal Madhukar tells investors in a research note. The analysts "feel better" about Snap daily active user growth, and the shares, after looking at the latest trends in the Snapchat self-serve ad platform data. They reiterate a Buy rating on Facebook and Hold rating on Snap. On the latter, the analysts cite their below consensus estimates and the stock's "lack valuation support" for staying neutral on Snap.
BMY Bristol-Myers
$56.45

-0.1 (-0.18%)

06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/19/18
06/19/18
DOWNGRADE
Target $300

In Line
Madrigal cut to In Line at Evercore ISI following run-up in price, expectations
As previously reported, Evercore ISI analyst Josh Schimmer downgraded Madrigal Pharmaceuticals (MDGL) to In Line from Outperform, stating that he has no real incremental reason to raise his $300 price target, which the stock has achieved following the company's encouraging Phase 2 results for MGL-3196 and a Bloomberg report that has driven takeover speculation. Given current investor sentiment, anything short of either an acquisition or a "massive" collaboration like Bristol-Myers' (BMY) with Nektar (NKTR) will fall short of expectations, Schimmer tells investors.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
LUV Southwest
$53.25

0.52 (0.99%)

06/15/18
06/15/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Southwest (LUV) downgraded to Hold from Buy at Argus with analyst John Staszak saying that despite being well managed and financially strong, its focus on the domestic market will lead to slower relative growth based on better expected performance in the international space. 2. Motorcar Parts (MPAA) downgraded to Neutral from Buy at Roth Capital with analyst Matt Koranda saying he expects margin erosion to intensify in the coming quarters as better industry growth is awaited. 3. BHP Billiton (BHP) and Rio Tinto (RIO) were downgraded to Hold from Buy at Investec. 4. AEGON (AEG) downgraded to Underperform from Neutral at BofA/Merrill with analyst Michael van Wegen citing "relatively strong" stock performance. 5. Splunk (SPLK) downgraded to Sell from Neutral at Citi with analyst Walter Pritchard saying he sees "growth drivers plateauing" and "some warning signs in numbers." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/18
EVER
06/18/18
NO CHANGE
Target $62
EVER
Outperform
Southwest added to Core Ideas List at Evercore ISI
Evercore ISI analyst Duane Pfennigwerth added Southwest to the firm's Core Ideas List following "encouraging" investor meetings with senior leadership, citing the stock's underperformance year-to-date, depressed investor sentiment, the company's network strength and its capital return and revenue improvement potential. He maintains an Outperform rating and $62 price target on Southwest shares.
07/03/18
DBAB
07/03/18
NO CHANGE
DBAB
Deutsche downgrades three airlines on 'headline risk' from trade dispute
Deutsche Bank analyst Michael Linenberg downgraded his ratings on American Airlines Group (AAL), Delta Air Lines (DAL) and United Continental (UAL) to Hold from Buy. The analyst cut his price target for American to $43 from $60, for Delta to $53 from $64 and for United to $74 from $81. In a world of "heightened" macroeconomic and geopolitical risks, economically-sensitive, high beta stocks such as airlines typically underperform the broader market, Linenberg tells investors in a research note. The possibility that the current trade dispute between the U.S. and its global partners could become something bigger is problematic for the airline industry's sales growth, the analyst adds. Further, Linenberg argues, the growing trade dispute may cause U.S. companies to reconsider their spending and employment plans, which would adversely impact corporate travel. As a result, the analyst sees "headline risk" and a lack of near-term catalysts for the airline stocks. He keeps Buy ratings on Alaska Air (ALK), Allegiant Travel (ALGT), JetBlue Airways (JBLU), Southwest Airlines (LUV), Spirit Airlines (SAVE) and SkyWest (SKYW).
06/15/18
ARGS
06/15/18
DOWNGRADE
ARGS
Hold
Southwest downgraded to Hold from Buy at Argus
As reported earlier, Argus analyst John Staszak downgraded Southwest Airlines to Hold from Buy, saying that despite being well managed and financially strong, its focus on the domestic market will lead to slower relative growth based on better expected performance in the international space. The analyst also anticipates Southwest to experience reduced near-term demand following the April accident which led to the death of one passenger, even as 2018 revenue benefits from the "sale of boarding slots, improvements in the frequent-flier program, a new reservation system, and a new credit card agreement with Chase". Staszak also lowers his FY18 EPS forecast to $4.70 from $4.90 and FY19 forecast to $5.20 from $5.50.
PEP PepsiCo
$107.78

-1.78 (-1.62%)

07/03/18
DBAB
07/03/18
DOWNGRADE
Target $116
DBAB
Hold
PepsiCo downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Stephen Powers downgraded PepsiCo to Hold with an unchanged price target of $116. The stock closed yesterday up 66c to $109.53. The analyst views the current valuation as a "bit bubbly." With at least 36 months of elevated investment, the stock's current risk/reward is fairly balanced, Powers tells investors in a research note.
07/03/18
07/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. United Continental (UAL), American Airlines (AAL), and Delta Airlines (DAL) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying in a world of "heightened" macroeconomic and geopolitical risks, economically-sensitive, high beta stocks such as airlines typically underperform the broader market. 2. Belmond (BEL) downgraded to Underweight from Overweight at Barclays with analyst Felicia Hendrix citing an analysis of the company's progress on its growth targets announced back in June 2016. 3. PSEG (PEG) downgraded to Hold from Buy at Deutsche Bank with analyst Jonathan Arnold saying The Federal Energy Regulatory Commission order raised new questions over New Jersey zero-emission credits. 4. PepsiCo (PEP) downgraded to Hold from Buy at Deutsche Bank with analyst Stephen Powers viewing the current valuation as a "bit bubbly." 5. Watsco (WSO), Fastenal (FAST), and Grainger (GWW) downgraded to Neutral from Outperform at Baird with analyst David Manthey saying he thinks the cycle and individual company results could remain solid for quarters or years to come, but he believes the cycle is in its later stages, thereby elevating risks to gross margins, rising labor costs, and earnings deceleration in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/06/18
WELS
07/06/18
NO CHANGE
Target $107
WELS
Market Perform
Wells Fargo cautious on PepsiCo fundamentals into Q2 results
Wells Fargo analyst Bonnie Herzog is cautious on PepsiCo's fundamentals ahead of the company's Q2 earnings results on July 10. The analyst reduced her fiscal 2018 and 2019 estimates to reflect continued weakness in North American beverages, lower sales in Latin America following the May trucker strike in Brazil and incremental currency headwinds. However, despite these continued pressures, the market could react favorably to PepsiCo management providing more details on their ultimate plans for the Beverage business, Herzog tells investors in a pre-earnings research note titled "PEP: We're Not Feeling So Bubly About PEP's Q2 Fundamentals." The analyst keeps a Market Perform rating on PepsiCo with a $107 price target.
07/09/18
RBCM
07/09/18
NO CHANGE
Target $111
RBCM
Sector Perform
PepsiCo to remain constrained by troubled Beverage business, says RBC Capital
RBC Capital analyst Nik Modi previews Q2 results for PepsiCo, saying he expects the trends of troubled North America Beverage business and poor earnings quality that have been on display over the past few quarters to persist. Modi further warns that FX and cost increases will worsen in this quarter, while the operating environment becomes more uncertain because of the threat of trade wars. The analyst keeps his Sector Perform rating and $111 price target on PepsiCo.
ENDP Endo
$11.22

0.365 (3.36%)

06/29/18
RILY
06/29/18
NO CHANGE
Target $13
RILY
Buy
Endo price target raised to $13 from $10 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Endo International to $13 saying he remains positive on the shares amidst the company's turnaround. The analyst keeps a Buy rating on the name.
05/02/18
RILY
05/02/18
INITIATION
Target $15
RILY
Neutral
Mallinckrodt initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst David Buck started Mallinckrodt (MNK) with a Neutral rating and $15 price target, as he believes its elevated leverage, decelerating revenues, and competitive threats offset the company's evolving pipeline opportunities. For those seeking a turnaround investment, Buck favors Endo International (ENDP), on which he has a Buy rating, he tells investors.
06/01/18
DBAB
06/01/18
NO CHANGE
Target $10
DBAB
Buy
Deutsche lowers Endo target to $10, keeps Buy rating
Deutsche Bank analyst Gregg Gilbert says that while it is difficult to predict when sentiment on Endo International could improve, the potential exists for greater visibility on some key overhangs over the next year or so. The stock is down 20% year-to-date as U.S. generic market pressures, Vasostrict risk, potential legal liabilities and high leverage continue to weigh on the stock, Gilbert tells investors in a research note. The analyst lowered his price target for Endo to $10 from $12 but keeps a Buy rating on the name. He believes it will be important to see continued stabilization for the generics business and new generic approvals for the stock to work.
06/27/18
SBSH
06/27/18
UPGRADE
SBSH
Buy
Endo upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Endo International to Buy from Hold, telling investors in a research note that he is moving off the sidelines. Abraham says he sees a "favorable" risk-reward profile at current levels, even after the recent upward inflection in the share price. He sees potential for an inflection in revenues in 2019 given continued execution on the base business, as well as the contribution of the Somerset acquisition.
SFIX Stitch Fix
$31.11

-1.3 (-4.01%)

03/13/18
JPMS
03/13/18
NO CHANGE
JPMS
Stitch Fix lock-up tomorrow could bring near-term weakness, says JPMorgan
JPMorgan analyst Doug Anmuth says active client growth modestly accelerated to 31% year-over-year, leading to Stitch Fix's fourth straight quarter of 25% year-over-year revenue growth. The analyst, however, keeps a Neutral rating on the shares with a $26 price target following last night's Q4 results. He expects advertising spend and headcount growth will continue to weigh on margins. Further, Anmuth estimates 31M shares will be released from lock-up tomorrow, March 14, before the market open, versus the current 9M share float. This could create near-term weakness in the shares, Anmuth tells investors in a research note.
03/19/18
BUCK
03/19/18
INITIATION
BUCK
Neutral
Stitch Fix initiated with a Neutral at Buckingham
06/22/18
WBLR
06/22/18
NO CHANGE
WBLR
William Blair does not see tax ruling impacting e-commerce companies
William Blair analyst Ryan Domyancic does not believe yesterday's Supreme Court ruling on state sales tax will have an adverse impact on the e-commerce companies he covers: Amazon.com (AMZN), Wayfair (W), and Stitch Fix (SFIX). He notes that his findings indicate that Amazon's price discount is not driven by a lack of sales tax. Further, Stitch Fix's primary value proposition is customized style rather than deep discounts, Domyancic tells investors in a research note. On Wayfair, the analyst thinks the collection of sales tax in incremental states has not affected its growth over the past several years.
07/09/18
KEYB
07/09/18
INITIATION
Target $38
KEYB
Overweight
Stitch Fix initiated with an Overweight at KeyBanc
KeyBanc started Stitch Fix with an Overweight rating and $38 price target.
ZNGA Zynga
$4.24

0.025 (0.59%)

05/29/18
PIPR
05/29/18
NO CHANGE
Target $5
PIPR
Overweight
Zynga price target raised to $5 from $4.25 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Zynga to $5 after spending several days with management. The analyst now has increased visibility regarding the company's prospects for consistent growth and margin expansion in 2018. While 2018 will be another year where Zynga focuses on live services from existing games, the company is building a pipeline of new titles and has several potential growth drivers, including ad revenue in Words With Friends 2 and chat based games, Olson tells investors in a research note. He maintains an Overweight rating on Zynga.
05/31/18
BNCH
05/31/18
NO CHANGE
Target $5
BNCH
Buy
Zynga price target raised to $5 after Gram Games deal at Benchmark
Benchmark analyst Mike Hickey raised his price target on Zynga to $5 from $4.36 and reiterated his Buy rating after the company announced the acquisition of mobile game developer Gram Games. He contends the "swimmingly boring" deal should drive considerable EBITDA growth while leveraging Zynga's strength in established genres. Hickey also believes this and other potential M&A along with new game launches should help drive bookings growth and continued EBITDA acceleration.
05/31/18
PIPR
05/31/18
NO CHANGE
Target $5
PIPR
Overweight
Zynga acquisition adds growing revenue stream, says Piper Jaffray
Piper Jaffray analyst Michael Olson says Zynga's $250M acquisition of Gram Games brings a profitably growing revenue stream. Gram brings a development team that has been responsible for several solid titles, including the company's most successful title, Merge Dragons, Olson tells investors in a research note. He believes Zynga is "building a pipeline of new titles and has several potential growth drivers." The analyst maintains an Overweight rating on the shares with a $5 price target.
05/30/18
BARD
05/30/18
NO CHANGE
Target $4
BARD
Neutral
Zynga deal consistent with previously laid out 'live' strategy, says Baird
After Zynga announced it had acquired privately-held mobile game maker Gram Games, Baird analyst Colin Sebastian said the deal is consistent with the company's previously laid out strategy around live services. He sees Zynga cross-selling titles across the respective gamer bases, creating customer acquisition efficiencies and improved monetization, and has confidence in Zynga management's recent execution track record, Sebastian tells investors. He keeps a Neutral rating and $4 price target on Zynga shares.
SGMS Scientific Games
$50.05

1.4 (2.88%)

02/20/18
JEFF
02/20/18
INITIATION
Target $57
JEFF
Buy
Scientific Games initiated with a Buy at Jefferies
Jefferies analyst David Katz started Scientific Games with a Buy rating and $57 price target. The analyst calls the company his Focus Pick in the equipment and technology supplier segment of the gaming industry. Katz views the current valuation as "highly attractive" following the NYX acquisition and his sum of the parts analysis yields share prices of $56 and $76 per share on 2018 and 2019 estimates.
10/05/17
CHLM
10/05/17
NO CHANGE
Target $56
CHLM
Buy
Scientific Games price target raised to $56 from $45 at Craig-Hallum
Craig-Hallum analyst Mike Malouf raised his price target for Scientific Games to $56 from $45 saying that its new CEO Kevin Sheehan has started to guide the company into the execution stage of its transformation. The new CEO has completed the cost rationalization initiative, which should further drive free cash flow this year, and the company is taking advantage of the market to refinance some of its debt, lowering the effective interest rate and driving continued free cash flow growth, he adds. Malouf reiterates a Buy rating on the shares.
05/15/18
BOFA
05/15/18
NO CHANGE
BOFA
Supreme Court ruling on sports betting positive for regionals, game tech, says BofA/Merrill
BofA/Merrill analyst Shaun Kelley notes that the Supreme Court ruled 6-3 to repeal the Professional and Amateur Sports Protection Act, which had effectively banned full sports betting in every state except Nevada. While the analyst expects operator margins to be low, he sees upside for all of regional gaming, while gaming tech could be a key beneficiary. Reflecting sports betting in higher multiples, Kelley raised his price targets for Boyd Gaming (BYD) to $45 from $42, Penn National (PENN) to $36 from $32, Scientific Games (SGMS) to $70 from $60, and International Game (IGT) to $36 from $34.
05/14/18
JEFF
05/14/18
NO CHANGE
JEFF
Jefferies says Penn National, Caesars among winners from sports gaming ruling
After the Supreme Court ruled that the PASPA provision prohibiting state authorization of organized sports gambling violates the tenth amendment, Jefferies analyst David Katz reiterated his view on which companies are positioned to be key beneficiaries of the decision. He continues to identify Penn National (PENN) and Caesars (CSR) as among the top winners in terms of casino operators, followed by Eldorado Resorts (ERI), Churchill Downs (CHDN), Boyd Gaming (BYD), Monarch Casino (MCRI), and MGM Resorts (MGM). He also sees "location-agnostic" suppliers Scientific Games (SGMS) and International Game (IGT) as winners, Katz tells investors.
PVG Pretium Resources
$9.30

1.205 (14.89%)

01/29/18
ROTH
01/29/18
NO CHANGE
Target $20
ROTH
Neutral
Market overreacted to Pretium Resources production results, guidance, says Roth Capital
Roth Capital analyst Joe Reagor notes that Pretium Resources has announced its Q4 2017 production results and provided initial guidance for 2018, with both items falling below his expectations. Nonetheless, the analyst believes the market overreacted to the news. He lowered his price target on the shares to $20 from $21, while reiterating a Buy rating on the stock.
01/25/18
CIBC
01/25/18
DOWNGRADE
CIBC
Neutral
Pretium Resources downgraded to Neutral from Outperformer at CIBC
01/23/18
FBCO
01/23/18
DOWNGRADE
Target $10
FBCO
Neutral
Pretium Resources downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Robert Reynolds downgraded Pretium Resources to Neutral from Outperform saying Q4 shows operational volatility. The analyst also lowered his price target on the shares to $10 from $13.50.
10/12/17
CIBC
10/12/17
UPGRADE
CIBC
Outperformer
Pretium Resources upgraded to Outperformer from Neutral at CIBC
PAH Platform Specialty Products
$12.40

0.66 (5.62%)

09/18/17
RHCO
09/18/17
UPGRADE
RHCO
Buy
Platform Specialty Products upgraded to Buy from Hold at SunTrust
SunTrust analyst James Sheehan upgraded Platform Specialty as he believes that the planned IPO of its agricultural unit in mid-2018, combined with an equity issuance, could raise its multiple, unlock value, and lessen its debt load. Target to $15 from $13.
06/07/18
MSCO
06/07/18
NO CHANGE
Target $12
MSCO
Equal Weight
Morgan Stanley says Platform Specialty investors likely prefer ag business sale
After The Wall Street Journal reported yesterday that Platform Specialty Products is in advanced talks to sell its agricultural unit to Wilmcote Holdings for about $3B, or $4B including debt, Morgan Stanley analyst Neel Kumar noted that the $4B reported offer from Wilmcote is lower than the $4.25B reportedly offered by a consortium led by Blackstone in July 2017. However, he thinks a potential sale could accelerate deleveraging and believes investors likely prefer an outright sale of the ag business to an IPO. Kumar keeps an Equal Weight rating and $12 price target on Platform Specialty shares.
11/15/17
11/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Albireo Pharma (ALBO) initiated with a Buy at Roth Capital. 2. Qudian (QD) was initiated with a Buy at Stifel and an Equal Weight at Morgan Stanley. 3. Platform Specialty Products (PAH) reinitiated with a Neutral at Credit Suisse. 4. Karyopharm (KPTI) assumed with a Buy at H.C. Wainwright. 5. Extraction Oil & Gas (XOG) initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/17
FBCO
11/15/17
INITIATION
Target $12
FBCO
Neutral
Platform Specialty Products reinitiated with a Neutral at Credit Suisse
Credit Suisse analyst Christopher Parkinson reinstated coverage of Platform Specialty Products with a Neutral rating and $12 price target.

TODAY'S FREE FLY STORIES

FRAC

Keane Group

$12.50

-0.14 (-1.11%)

19:33
10/17/18
10/17
19:33
10/17/18
19:33
Initiation
Keane Group initiated  »

Keane Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NBR

Nabors Industries

$6.25

-0.175 (-2.72%)

19:28
10/17/18
10/17
19:28
10/17/18
19:28
Initiation
Nabors Industries initiated  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

NINE

Nine Energy Services

$39.10

0.31 (0.80%)

19:19
10/17/18
10/17
19:19
10/17/18
19:19
Initiation
Nine Energy Services initiated  »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PTEN

Patterson-UTI

$16.58

-0.37 (-2.18%)

19:17
10/17/18
10/17
19:17
10/17/18
19:17
Initiation
Patterson-UTI initiated  »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

GSBC

Great Southern Bancorp

$52.51

0.26 (0.50%)

19:04
10/17/18
10/17
19:04
10/17/18
19:04
Earnings
Great Southern Bancorp reports preliminary Q3 EPS $1.18, consensus $1.06 »

Reports Q3 NI $43.0M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

HMNY

Helios and Matheson

$0.02

0.001 (5.18%)

18:59
10/17/18
10/17
18:59
10/17/18
18:59
Periodicals
Breaking Periodicals news story on Helios and Matheson »

Helios & Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BY

Byline Bancorp

$21.33

0.02 (0.09%)

18:51
10/17/18
10/17
18:51
10/17/18
18:51
Hot Stocks
Byline Bancorp to acquire Oak Park River Forest Bankshares for $42M »

Byline Bancorp and Oak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ABB

ABB

$21.37

-0.115 (-0.54%)

18:48
10/17/18
10/17
18:48
10/17/18
18:48
Periodicals
ABB weighs divesting $10B power grid business, Bloomberg reports »

ABB is working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEC

Vectrus

$28.98

-0.74 (-2.49%)

18:22
10/17/18
10/17
18:22
10/17/18
18:22
Hot Stocks
Vectrus names Kevin Boyle chief legal officer »

Vectrus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$6.41

-0.005 (-0.08%)

18:21
10/17/18
10/17
18:21
10/17/18
18:21
Hot Stocks
Sprint extends credits to Florida customers impacted by Hurricane Michael »

Sprint said it continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TALO

Talos Energy

$29.85

-1.49 (-4.75%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Talos Energy reaches pact with Hokchi to cross-assign interests »

Talos Energy Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Steel Dynamics CEO says 'delivered a tremendous third quarter performance' »

"The team delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:02
10/17/18
10/17
18:02
10/17/18
18:02
Hot Stocks
Steel Dynamics CEO: We believe steel consumption will continue to be strong »

"We remain confident…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:01
10/17/18
10/17
18:01
10/17/18
18:01
Earnings
Steel Dynamics reports Q3 adjusted EPS $1.69, consensus $1.64 »

Reports Q3 revenue $3.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRTO

Criteo

$23.00

-0.29 (-1.25%)

, RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

17:44
10/17/18
10/17
17:44
10/17/18
17:44
Periodicals
Advertising technology firm DataXu exploring sale, WSJ says »

DataXu, which offers…

CRTO

Criteo

$23.00

-0.29 (-1.25%)

RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

FUEL

Rocket Fuel

$0.00

(0.00%)

GOOG

Alphabet

$1,115.99

-4.12 (-0.37%)

FB

Facebook

$159.46

0.65 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 16

    Nov

  • 03

    Mar

BTU

Peabody Energy

$36.09

-0.31 (-0.85%)

17:37
10/17/18
10/17
17:37
10/17/18
17:37
Hot Stocks
Peabody Energy increases quarterly dividend nearly 4% to 13c per share »

Peabody Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:34
10/17/18
10/17
17:34
10/17/18
17:34
Earnings
Brandywine Realty sees FY19 FFO $1.37-$1.47, consensus $1.44 »

Sees FY17 EPS 36c-46c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:33
10/17/18
10/17
17:33
10/17/18
17:33
Earnings
Brandywine Realty narrows FY18 FFO view to $1.36-$1.40 from $1.35-$1.41 »

Consensus for FY18 FFO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Earnings
Brandywine Realty reports Q3 FFO 35c, consensus 35c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BPRN

Bank of Princeton

$30.75

-0.16 (-0.52%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Hot Stocks
Bank of Princeton declares initial cash dividend of 3c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$32.01

-0.25 (-0.77%)

, AMZN

Amazon.com

$1,832.81

14.81 (0.81%)

17:26
10/17/18
10/17
17:26
10/17/18
17:26
Periodicals
eBay sues Amazon, claims sellers were illegally poached, WSJ says »

eBay (EBAY) has filed a…

EBAY

eBay

$32.01

-0.25 (-0.77%)

AMZN

Amazon.com

$1,832.81

14.81 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 30

    Oct

  • 03

    Mar

OIS

Oil States

$29.77

-0.13 (-0.43%)

17:18
10/17/18
10/17
17:18
10/17/18
17:18
Earnings
Oil States sees Q3 revenue at low end of $273M-$298M, consensus $288.81M »

Oil States announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$45.90

-0.03 (-0.07%)

17:15
10/17/18
10/17
17:15
10/17/18
17:15
Periodicals
Intel 'shakes up' manufacturing unit amid production missteps, Oregonian says »

Sohail Ahmed, who has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NOC

Northrop Grumman

$309.25

-2.87 (-0.92%)

17:15
10/17/18
10/17
17:15
10/17/18
17:15
Hot Stocks
Northrop Grumman awarded $697.03M Navy contract »

Northrop Grumman doing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:14
10/17/18
10/17
17:14
10/17/18
17:14
Hot Stocks
Crown Holdings CEO says Q3 performance 'solid' »

Commenting on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.